Focused On-demand Library for Transmembrane protein 230

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96A57

UPID:

TM230_HUMAN

Alternative names:

Alternative UPACC:

Q96A57; B2RDM8; D3DVZ9; Q0VGC8; Q5TDS5; Q96ES2; Q9P0A7

Background:

Transmembrane protein 230 (TMEM230) plays a crucial role in the trafficking and recycling of synaptic vesicles, essential for neurotransmitter release and synaptic transmission. This protein's involvement in these processes underscores its importance in maintaining normal brain function and neural communication.

Therapeutic significance:

Given its association with Parkinson disease, a neurodegenerative disorder marked by the loss of dopaminergic neurons and presence of Lewy bodies, TMEM230's study is pivotal. Understanding TMEM230's role could lead to novel therapeutic strategies for managing Parkinson's disease, focusing on its genetic variants and their contribution to disease pathogenesis.